Clinical and Translational Research
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2022; 13(2): 135-146
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.135
Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas
Athina Stravodimou, Ioannis A Voutsadakis
Athina Stravodimou, Department of Medical Oncology, CHUV, Lausanne 1011, Switzerland
Ioannis A Voutsadakis, Department of Medical Oncology, Sault Area Hospital, Sault Ste Marie P6B0A8, Ontario, Canada
Author contributions: Both authors contributed to the conception of the study, literature review, data analysis, writing of the article and revising the article.
Institutional review board statement: No institutional review board approval was required or obtained as the study was not a clinical trial.
Clinical trial registration statement: This study was not registered as a clinical trial as it includes only data from publicly available previously published studies and no new patient information.
Informed consent statement: No informed consents have been obtained for this study as no new patients were included. The study analyzed publicly available data from previously published studies.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Ioannis A Voutsadakis, MD, PhD, Associate Professor, Doctor, Department of Medical Oncology, Sault Area Hospital, 750 Great Northern Road, Sault Ste Marie P6B0A8, Ontario, Canada.
Received: April 5, 2021
Peer-review started: April 5, 2021
First decision: July 6, 2021
Revised: July 11, 2021
Accepted: January 13, 2022
Article in press: January 13, 2022
Published online: February 24, 2022
Core Tip

Core Tip: Molecular lesions in neurotrophic receptor tyrosine kinase (NTRK) receptors have been brought to the forefront of cancer therapy with the introduction of specific inhibitors which are effective in cancers with fusions involving the family of receptors. In breast cancer fusions involving the NTRK receptors are rarely seen and concern exclusively the secretory sub-type. In non-secretory breast carcinomas amplifications are observed in a minority of cases.